Immune cells in pancreatic cancer: Joining the dark side.

abstract：:VXM01 is a first-in-kind orally applied tumor vaccine based on live attenuated Salmonella typhi carrying an expression plasmid encoding VEGFR2, an antigen expressed on tumor vasculature and a stable and accessible target for anti-angiogenic intervention. A recent randomized, placebo-controlled, phase I dose-escalation...

journal_title：Oncoimmunology

authors： Schmitz-Winnenthal FH,Hohmann N,Schmidt T,Podola L,Friedrich T,Lubenau H,Springer M,Wieckowski S,Breiner KM,Mikus G,Büchler MW,Keller AV,Koc R,Springfeld C,Knebel P,Bucur M,Grenacher L,Haefeli WE,Beckhove P

更新日期：2018-01-16 00:00:00

abstract：:Immune evasion of tumors poses a major challenge for immunotherapy. For human papillomavirus (HPV)-induced malignancies, multiple immune evasion mechanisms have been described, including altered expression of antigen processing machinery (APM) components. These changes can directly influence epitope presentation and t...

journal_title：Oncoimmunology

authors： Steinbach A,Winter J,Reuschenbach M,Blatnik R,Klevenz A,Bertrand M,Hoppe S,von Knebel Doeberitz M,Grabowska AK,Riemer AB

更新日期：2017-06-20 00:00:00

abstract：:Oncolytic viruses (OVs) preferentially target and kill cancer cells without affecting healthy cells through a multi-modal mechanism of action. While historically the direct killing activity of OVs was considered the primary mode of action, initiation or augmentation of a host antitumor immune response is now considere...

journal_title：Oncoimmunology

authors： Davola ME,Mossman KL

更新日期：2019-03-28 00:00:00

abstract：:Introduction: PD-1 inhibitors have been approved for the treatment of dMMR patients with metastatic colorectal cancer, but the efficacy of neoadjuvant treatment with PD-1 in dMMR locally advanced rectal cancer (LARC) patients has not yet been defined. Patients and methods: Two patients with LARC received Nivolumab as ...

journal_title：Oncoimmunology

authors： Zhang J,Cai J,Deng Y,Wang H

更新日期：2019-09-19 00:00:00

abstract：:Macrophages in the tumor microenvironment respond to complex cytokine signals. How these responses shape the phenotype of tumor-associated macrophages (TAMs) is incompletely understood. Here we explored how cytokines of the tumor milieu, interleukin (IL)-6 and IL-4, interact to influence target gene expression in prim...

journal_title：Oncoimmunology

authors： Gupta S,Jain A,Syed SN,Snodgrass RG,Pflüger-Müller B,Leisegang MS,Weigert A,Brandes RP,Ebersberger I,Brüne B,Namgaladze D

更新日期：2018-07-30 00:00:00

abstract：:Human pancreatic ductal adenocarcinoma (PDAC) exhibits marginal responses to anti-PD-1/PD-L1 immunotherapy and its mechanism remains poorly understood. We have investigated the effect of anti-PD-L1 and c-Myc inhibition in PDAC. Using 87 patients with PDAC from our hospital database we found a significant correlation b...

journal_title：Oncoimmunology

authors： Pan Y,Fei Q,Xiong P,Yang J,Zhang Z,Lin X,Pan M,Lu F,Huang H

更新日期：2019-03-01 00:00:00

abstract：:Alkylating chemotherapy exerts both antineoplastic and immunostimulatory effects. However, in addition to depleting regulatory T cells (Treg), alkylating agents also mediate a long lasting antiproliferative effect on responder lymphocytes. Our recent findings indicate that this antiproliferative effect profoundly impa...

journal_title：Oncoimmunology

authors： Litterman AJ,Dudek AZ,Largaespada DA

更新日期：2013-10-01 00:00:00

abstract：:Adoptive cell transfer (ACT) is an emerging anticancer therapy that has shown promise in various malignancies. Redirecting antigen specificity by genetically engineering T cells to stably express receptors has become an effective variant of ACT. A novel extension of this approach is to utilize engineered T cells to pr...

journal_title：Oncoimmunology

authors： Tsai AK,Davila E

更新日期：2016-01-15 00:00:00

abstract：:We have developed a recombinant adenovirus vaccine encoding dopachrome tautomerase (rHuAd5-hDCT) that produces robust DCT-specific immunity, but only provides modest suppression of murine melanoma. In the current study, an agonist antibody against 4-1BB was shown to enhance rHuAd5-hDCT efficacy and evoke tumor regress...

journal_title：Oncoimmunology

authors： McGray AJ,Bernard D,Hallett R,Kelly R,Jha M,Gregory C,Bassett JD,Hassell JA,Pare G,Wan Y,Bramson JL

更新日期：2012-07-01 00:00:00

abstract：:Glioblastoma (GBM) is the most aggressive malignant primary brain tumor in adults, with a median survival of 14.6 months. Recent efforts have focused on identifying clinically relevant subgroups to improve our understanding of pathogenetic mechanisms and patient stratification. Concurrently, the role of immune cells i...

journal_title：Oncoimmunology

authors： Kaffes I,Szulzewsky F,Chen Z,Herting CJ,Gabanic B,Velázquez Vega JE,Shelton J,Switchenko JM,Ross JL,McSwain LF,Huse JT,Westermark B,Nelander S,Forsberg-Nilsson K,Uhrbom L,Maturi NP,Cimino PJ,Holland EC,Kettenmann H,

更新日期：2019-08-22 00:00:00

abstract：:Monoclonal antibodies (mAb) induce tumor regression through antibody-dependant cellular cytotoxicity (ADCC). We recently showed that an agonistic anti-CD137 mAb stimulates natural killer (NK) cells which have been activated by a tumor-specific mAb, resulting in increased ADCC against cancer cells. ...

journal_title：Oncoimmunology

authors： Houot R,Kohrt H,Levy R

更新日期：2012-09-01 00:00:00

abstract：:In combination cancer immunotherapies, consideration should be given to designing treatment schedules that harmonize with the immune system's natural timing. An efficacious temporally programmed combination therapy of extended half-life interleukin 2 (eIL2), tumor targeting antibody, and interferon (IFN) α was recentl...

journal_title：Oncoimmunology

authors： Rothschilds A,Tzeng A,Mehta NK,Moynihan KD,Irvine DJ,Wittrup KD

更新日期：2019-02-19 00:00:00

abstract：:Pancreatic cancer is characterized by expanded stroma with marked fibrosis. In Ijichi et al., we show that inhibiting CXCR2 disrupts tumor-stromal interactions and improves survival of a genetically-engineered mouse model recapitulating human pancreatic cancer. Targeting CXCLs/CXCR2 axis in the tumor microenvironment ...

journal_title：Oncoimmunology

authors： Ijichi H

更新日期：2012-07-01 00:00:00

abstract：:Dendritic cells (DCs) occupy a privileged position at the interface between innate and adaptive immunity, orchestrating a large panel of responses to both physiological and pathological cues. In particular, whereas the presentation of antigens by immature DCs generally results in the development of immunological toler...

journal_title：Oncoimmunology

authors： Vacchelli E,Vitale I,Eggermont A,Fridman WH,Fučíková J,Cremer I,Galon J,Tartour E,Zitvogel L,Kroemer G,Galluzzi L

更新日期：2013-10-01 00:00:00

abstract：:Regulatory T cells (Tregs) can prevent graft-vs.-host disease as induced by the infusion of donor lymphocytes to cancer patients, but often they also suppress therapeutic antitumor immunity. We discuss an exception to this phenomenon, exemplifying how the milieu provided by the bone marrow may neutralize Tregs to allo...

journal_title：Oncoimmunology

authors： Guichelaar T,Mutis T

更新日期：2013-07-01 00:00:00

abstract：:Sepsis-induced immune dysfunctions are likely to impact on malignant tumor growth. Sequential sepsis-then-cancer models of tumor transplantation in mice recovering from sepsis have shown that the post-septic immunosuppressive environment was able to promote tumor growth. We herein addressed the impact of sepsis on pre...

journal_title：Oncoimmunology

authors： Vigneron C,Mirouse A,Merdji H,Rousseau C,Cousin C,Alby-Laurent F,Mira JP,Chiche JD,Llitjos JF,Pène F

更新日期：2019-07-19 00:00:00

abstract：:We have previously reported a novel phenotype of myeloid suppressors in lymphoma patients characterized by a loss of HLA-DR expression on monocytes, CD14+HLA-DRlow/neg. These cells were directly immunosuppressive and were associated with poor clinical outcome. In this study, we found that lymphoma tumors could have mo...

journal_title：Oncoimmunology

authors： Zhang ZJ,Bulur PA,Dogan A,Gastineau DA,Dietz AB,Lin Y

更新日期：2015-01-26 00:00:00

abstract：:Immunotherapies such as adoptive cell therapy (ACT) are promising treatments for solid cancers. However, relapsing disease remains a problem and the molecular mechanisms underlying resistance are poorly defined. We postulated that the deregulated epigenetic landscape in cancer cells could underpin the acquisition of r...

journal_title：Oncoimmunology

authors： Wylie B,Chee J,Forbes CA,Booth M,Stone SR,Buzzai A,Abad A,Foley B,Cruickshank MN,Waithman J

更新日期：2019-06-03 00:00:00

abstract：:We have developed a highly versatile platform for the systematic retrieval of T-cell receptors (TCRs) from single-antigen-reactive T cells and for characterization of their function and specificity. This approach enables rapid extraction of multiple TCRs from repertoires in individuals and not only broadens the divers...

journal_title：Oncoimmunology

authors： Omokoko T,Simon P,Türeci Ö,Sahin U

更新日期：2015-03-19 00:00:00

abstract：:Interleukin (IL)-17A belongs to IL-17 superfamily and binds the heterodimeric IL-17 receptor (R)(IL-17RA/IL-17RC). IL-17A promotes germinal center (GC) formation in mouse models of autoimmune or infectious diseases, but the role of IL-17A/IL-17AR complex in human neoplastic GC is unknown. In this study, we investigate...

journal_title：Oncoimmunology

authors： Ferretti E,Di Carlo E,Ognio E,Guarnotta C,Bertoni F,Corcione A,Prigione I,Fraternali-Orcioni G,Ribatti D,Ravetti JL,Ponzoni M,Tripodo C,Pistoia V

更新日期：2015-06-19 00:00:00

abstract：:DNA vaccination consists of administering an antigen-coding nucleotide sequence. In order to improve the efficacy of DNA vaccines, electroporation is one of the most commonly used methods to enhance DNA uptake. Here, we discuss additional immunological effects of electroporation that are key aspects for inducing immun...

journal_title：Oncoimmunology

authors： Calvet CY,André FM,Mir LM

更新日期：2014-04-29 00:00:00

abstract：:PD-L1 expression and regulation by mesenchymal tumor cells remain largely undefined. Here, we report that among different EMT-activated MCF7 human breast cancer cell clones, PD-L1 was differentially upregulated in MCF7 sh-WISP2, MCF7-1001/2101, and MDA-MB-231 cells but not in MCF7 SNAI1 and MCF7 SNAI1-6SA cells. Mecha...

journal_title：Oncoimmunology

authors： Noman MZ,Janji B,Abdou A,Hasmim M,Terry S,Tan TZ,Mami-Chouaib F,Thiery JP,Chouaib S

更新日期：2017-01-23 00:00:00

abstract：:PD-1 engagement on the surface of effector T cells strongly suppresses their cytotoxic function, which constitutes a major obstacle for T cell-mediated anti-tumor activities. Surprisingly, PD-1 is strongly upregulated in T cells, engaging its ligand PD-L1 during antigen presentation. However, our recent published data...

journal_title：Oncoimmunology

authors： Karwacz K,Arce F,Bricogne C,Kochan G,Escors D

更新日期：2012-01-01 00:00:00

abstract：:Merkel cell carcinoma (MCC) is a rare skin cancer caused by Merkel cell polyomavirus (MCPyV) infection and/or ultraviolet radiation-induced somatic mutations. The presence of tumor-infiltrating lymphocytes is evidence that an active immune response to MCPyV and tumor-associated neoantigens occurs in some patients. How...

journal_title：Oncoimmunology

authors： Schadendorf D,Nghiem P,Bhatia S,Hauschild A,Saiag P,Mahnke L,Hariharan S,Kaufman HL

更新日期：2017-08-31 00:00:00

abstract：:The redirection of T cell activity using bispecific antibodies is one of the most promising cancer immunotherapy approaches currently in development, but it is limited by cytokine storm-related toxicities, as well as the pharmacokinetics and tumor-penetrating capabilities of current bispecific antibody formats. Here, ...

journal_title：Oncoimmunology

authors： Harwood SL,Alvarez-Cienfuegos A,Nuñez-Prado N,Compte M,Hernández-Pérez S,Merino N,Bonet J,Navarro R,Van Bergen En Henegouwen PMP,Lykkemark S,Mikkelsen K,Mølgaard K,Jabs F,Sanz L,Blanco FJ,Roda-Navarro P,Alvarez-Vallina L

更新日期：2017-09-27 00:00:00

abstract：:Programmed death ligand 1 (PD-L1) expression represents a mechanism of immune escape by inhibiting T cell immunity. This study systematically evaluated the expression of PD-L1, spatial distribution of CD3+ immune cells and the relationship of both factors to survival in nasopharyngeal carcinoma (NPC) patients. A total...

journal_title：Oncoimmunology

authors： Zhu Q,Cai MY,Chen CL,Hu H,Lin HX,Li M,Weng DS,Zhao JJ,Guo L,Xia JC

更新日期：2017-04-27 00:00:00

abstract：:Despite the opposite roles of Tbet and Foxp3 in the immune system as well as in tumour biology, recent studies have demonstrated the presence of of CD4+ T cells, expressing both, Tbet and Foxp3. Although Tbet+Foxp3+ T cells are currently a subject of intense research, less is known about their biological function espe...

journal_title：Oncoimmunology

authors： Kachler K,Holzinger C,Trufa DI,Sirbu H,Finotto S

更新日期：2018-04-25 00:00:00

abstract：:Three recent publications identified the TNF/TNR2 pathway as a new target to reduce graft-versus-host-disease through regulatory T cells activation or to potentially switch on a strong anti-leukemic effect through regulatory T cells blockade in allogeneic hematopoietic stem cell transplantation. This identified the TN...

journal_title：Oncoimmunology

authors： Cohen JL,Wood KJ

更新日期：2017-09-21 00:00:00

abstract：:Interleukin (IL)-10 is a major cancer-related immunosuppressive factor, exhibiting a unique ability to hamper the maturation of dendritic cells (DCs). We have previously reported that IL-10 induces the conversion of activated, migratory CD1a+ DCs found in the human skin to CD14+CD141+ macrophage-like cells. Here, as a...

journal_title：Oncoimmunology

authors： Lindenberg JJ,van de Ven R,Lougheed SM,Zomer A,Santegoets SJ,Griffioen AW,Hooijberg E,van den Eertwegh AJ,Thijssen VL,Scheper RJ,Oosterhoff D,de Gruijl TD

更新日期：2013-04-01 00:00:00

abstract：:Lung-specific overexpression of prostacyclin synthase (PGIS) decreases tumor initiation in murine lung cancer models. Prostacyclin analogs prevent lung tumor formation in mice and reverse bronchial dysplasia in former smokers. However, the effect of prostacyclin on lung cancer progression has not been well studied. We...

journal_title：Oncoimmunology

authors： Li HY,McSharry M,Walker D,Johnson A,Kwak J,Bullock B,Neuwelt A,Poczobutt JM,Sippel TR,Keith RL,Weiser-Evans MCM,Clambey E,Nemenoff RA

更新日期：2018-02-13 00:00:00